Acadia Pharmaceuticals (ACAD) Receivables (2016 - 2026)

Acadia Pharmaceuticals has reported Receivables for 11 years, with the latest figure at $148.4 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 30.49% year-over-year to $148.4 million; the trailing twelve-month figure through Mar 2026 stood at $148.4 million (up 30.49% YoY), and the FY2025 full-year result was $148.2 million, up 41.58% from the prior year.
• Receivables for Q1 2026 stood at $148.4 million, roughly flat from $148.2 million in the prior quarter.
• The five-year high for Receivables was $148.4 million in Q1 2026, with the low at $56.1 million in Q3 2022.
• Average Receivables over 5 years is $99.9 million, with a median of $102.4 million recorded in 2023.
• Year-over-year, Receivables slipped 8.97% in 2022 and surged 68.4% in 2023.
• Tracing ACAD's Receivables over 5 years: stood at $63.1 million in 2022, then surged by 62.25% to $102.4 million in 2023, then rose by 2.29% to $104.7 million in 2024, then soared by 41.58% to $148.2 million in 2025, then climbed by 0.1% to $148.4 million in 2026.
• The last three Receivables figures came in at $148.4 million (Q1 2026), $148.2 million (Q4 2025), and $139.4 million (Q3 2025), per Business Quant data.

Peer Comparison